Assessment of the plasma levels of Growth Differentiation Factor 11 as a potential distinguishing biomarker between essential thrombocytosis and bone marrow myelofibrosis
Previous studies address the role of GDF11 in initiation and progression of fibrosis in different pathological conditions. However, its role in bone marrow fibrosis is not previously addressed. This study aimed to assess plasma levels as possible differentiating biomarker between essential thrombocytosis (ET) and bone marrow myelofibrosis (MF).
Materials and Methods/Case Presentation/Objective:
This study included 78 patients diagnosed as ET, 44 patients with MF and 100 control subjects. For all studied groups plasma GDF11 levels was assessed by ELISA.
Results/Description/Main Outcome Measure(s):
The platelets count is significantly higher in the ET group when compared to both the MF and control groups, whereas the MF group exhibited a notable decrease in platelet count relative to the control group. The concentration of plasma GDF11 levels are markedly higher in the ET group as compared to MF group followed by control group. No significant association between the presence or absence of genetic mutations (JAK2, CALR) in relation to GDF11plasma levels in ET and MF. ROC analysis revealed that the best cut-off value for GDF11 plasma levels is 4.7, which can distinguish between ET and MF with a sensitivity of 90.9% and a specificity of 100%.
Conclusion(s).: GDF11 plasma levels could serve as novel biomarker that could differentiate between ET and MF
Trademarked Items: GDF11, ET, MF
References:
